36 Results for "

Metastatic lung tumors

" in MedChemExpress (MCE) Product Catalog:
Products (36)

36 Results for "Metastatic lung tumors" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-101488
CAS No.: 1010100-07-8
Purity:  99.85%
CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a Kd of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-136174
CAS No.: 2381037-82-5
Purity:  99.86%
Target:  

PARP

Research Areas:  

Cancer

RBN-2397 is a potent, accross species and orally active NAD + competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114169
CAS No.: 1913291-02-7
Purity:  99.76%
Research Areas:  

Inflammation/Immunology Cancer

WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic breast tumor cell colonization in the lungs. WRG-28 also shows good activity of relieving rheumatoid arthritis in CAIA model of mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N6893
CAS No.: 54999-07-4
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-106033
CAS No.: 204318-14-9
Purity:  98.15%
Synonyms: DOTATOC; SDZ-SMT 487; SMT 487
Research Areas:  

Cancer

Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114358
CAS No.: 1646839-59-9
Purity:  98.59%
Synonyms: ONO-7475
Research Areas:  

Cancer

Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-119217
CAS No.: 929300-19-6
Purity:  99.65%
Target:  

CCR

AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma . AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-118487
CAS No.: 939825-12-4
Purity:  98.03%
Research Areas:  

Cancer

OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164789
CAS No.: 2768350-77-0
Synonyms: SKB264; MK-2870
Research Areas:  

Cancer

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/mL, TROP2 Kd of 0.3083 nM, and topoisomerase I IC50 of 0.7 μM. Sacituzumab tirumotecan is composed of the humanized anti-TROP2 antibody Sacituzumab (HY-P99045), the drug-linker conjugate for ADC is TL033 TFA (HY-147340A). Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13747
CAS No.: 13909-09-6
Purity:  ≥98.0%
Research Areas:  

Cancer

Semustine is an orally active, blood-brain barrier permeable antitumor alkylating agent with a binding affinity of 1.53 × 10 3 M -1 for guanine and thymine residues in bovine DNA. Semustine undergoes major groove-directed alkylation at guanine residues to form O6-chloroethylguanine and N1-O6-ethanoguanine adducts, and generates dG-dC interstrand crosslinks. Semustine induces partial B- to C-type transition of DNA, base stacking and helical structure distortion, mild dehydration, as well as partial DNA double-strand unwinding. Semustine can be used in research related to Lewis lung cancer, leukemia, Hodgkin's lymphoma, malignant melanoma, glioma, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P991097
Synonyms: PM-8002; BNT-327

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-P990940
CAS No.: 2883118-92-9
Synonyms: MBE-748; M-9140 Antibody; MBE-2882 Antibody

Research Areas:  

Cancer

Precemtabart is a humanized IgG1 antibody targeting CEACAM5, with selectivity for CEACAM5-positive cells. Precemtabart binds to CEACAM5 on tumor cells to deliver the topoisomerase 1 inhibitor Exatecan (HY-13631), and induces cell death by inhibiting the function of TOP1. Precemtabart inhibits the growth of CEACAM5-positive cancer cells. Precemtabart causes dose-dependent hematolymphoid and intestinal-related effects in cynomolgus monkeys. Precemtabart can be used in research related to metastatic colorectal cancer, metastatic pancreatic ductal carcinoma, advanced gastric cancer, advanced non-small cell lung cancer, and advanced pancreatic adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P990704
CAS No.: 2640305-01-5
Synonyms: AZD-2936

Research Areas:  

Cancer

Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .
loading...
    loading...
Cat. No.: HY-12168
CAS No.: 179545-77-8
Purity:  99.7%
Synonyms: BAY 12-9566
Target:  

MMP

Research Areas:  

Cancer

Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .
loading...
    loading...
Cat. No.: HY-P991106
Synonyms: LY-3076226 antibody

Target:  

FGFR ADC Antibodies

Research Areas:  

Cancer

IMC-D11 (LY-3076226 antibody) is an anti-FGFR3 IgG1 monoclonal antibody with an EC50 of approximately 0.1 nM against hFGFR3b and hFGFR3c. IMC-D11 inhibits the growth of FGFR3-dependent lung adenocarcinoma in mouse models and shows no effect on tumors that do not express FGFR3. IMC-D11 can serve as an ADC Antibody for ADC synthesis, such as LY3076226. IMC-D11 is applicable to research related to urothelial carcinoma, multiple myeloma, lung adenocarcinoma, as well as advanced or metastatic cancers .
loading...
    loading...
Cat. No.: HY-164429
CAS No.: 2418533-90-9
Target:  

Integrin Elastase

Research Areas:  

Cancer

VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
loading...
    loading...
Cat. No.: HY-P991402

Target:  

TNF Receptor NF-κB

Research Areas:  

Cancer

BI-1910 is an agonistic human IgG2 monoclonal antibody targeting TNFR2, which selectively binds to human TNFR2 without inhibiting TNF-α binding. As an endogenous agonist, BI-1910 activates TNFR2 and mediates the activation of the NF-κB signaling pathway. Its agonistic activity is independent of FcγR or cross-linking; it can directly costimulate T cells and NK cells, induce T cell proliferation, and activate tumor-specific CD8+ T cells. BI-1910 exhibits antitumor activity in vivo, and shows an additive antitumor effect when combined with anti-PD-1 (HY-P9902). It can be used in research related to advanced/metastatic non-small cell lung cancer and hepatocellular carcinoma. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
loading...
    loading...
Cat. No.: HY-P11356
CAS No.: 1932689-39-8
Target:  

Ras MHC

Research Areas:  

Cancer

KRAS G12V Peptide is a polypeptide and epitope derived from KRAS G12V. KRAS G12V Peptide forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide is applicable to research related to metastatic lung cancer .
loading...
    loading...
Cat. No.: HY-P11356A
Target:  

Ras MHC

Research Areas:  

Cancer

KRAS G12V Peptide TFA is a polypeptide and epitope derived from KRAS G12V. KRAS G12V Peptide TFA forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide TFA is applicable to research related to metastatic lung cancer .
loading...
    loading...